NYSE:CTLT (USA) Also trade in: Germany

Catalent Inc

$ 46 -0.01 (-0.02%)
Volume: 278,352 Avg Vol (1m): 788,313
Market Cap $: 6.73 Bil Enterprise Value $: 8.69 Bil
P/E (TTM): 43.60 P/B: 4.19
Earnings Power Value 3.91
Net Current Asset Value -11.78
Tangible Book -2.34
Projected FCF 14.32
Median P/S Value 34.21
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.10
Cash-To-Debt ranked lower than
87.89% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
CTLT: 0.1
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.02, Med: 0.07, Max: 0.29
Current: 0.1
0.02
0.29
Equity-to-Asset 0.36
Equity-to-Asset ranked lower than
90.61% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
CTLT: 0.36
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.14, Med: 0.2, Max: 0.36
Current: 0.36
-0.14
0.36
Debt-to-Equity 1.35
Debt-to-Equity ranked lower than
96.81% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
CTLT: 1.35
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -7.65, Med: 2.73, Max: 4.02
Current: 1.35
-7.65
4.02
Debt-to-EBITDA 4.32
Debt-to-EBITDA ranked lower than
83.03% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
CTLT: 4.32
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 4.32, Med: 6, Max: 8.12
Current: 4.32
4.32
8.12
Interest Coverage 2.64
Interest Coverage ranked lower than
89.35% of 648 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
CTLT: 2.64
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 1.12, Med: 2.11, Max: 2.8
Current: 2.64
1.12
2.8
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.06
DISTRESS
GREY
SAFE
Beneish M-Score -2.44
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 7.28%
WACC 11.49%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 11.73
Operating Margin ranked higher than
62.55% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
CTLT: 11.73
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 11.73, Med: 12.8, Max: 15.18
Current: 11.73
11.73
15.18
Net Margin % 6.01
Net Margin ranked lower than
60.47% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
CTLT: 6.01
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -3.53, Med: 2.14, Max: 11.59
Current: 6.01
-3.53
11.59
ROE % 10.85
ROE ranked higher than
53.73% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
CTLT: 10.85
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 9.24, Med: 16.86, Max: 161.49
Current: 10.85
9.24
161.49
ROA % 3.31
ROA ranked lower than
56.14% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
CTLT: 3.31
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -1.63, Med: 2.09, Max: 6.81
Current: 3.31
-1.63
6.81
ROC (Joel Greenblatt) % 17.01
ROC (Joel Greenblatt) ranked higher than
65.38% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
CTLT: 17.01
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 17.01, Med: 20.19, Max: 41.21
Current: 17.01
17.01
41.21
3-Year Total Revenue Growth Rate 10.40
3-Year Revenue Growth Rate ranked lower than
86.79% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
CTLT: 7
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -1.5, Med: 1.7, Max: 7
Current: 7
-1.5
7
3-Year Total EBITDA Growth Rate 8.20
3-Year EBITDA Growth Rate ranked lower than
84.66% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
CTLT: 4.9
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -2.6, Med: 1.7, Max: 10.7
Current: 4.9
-2.6
10.7
3-Year EPS w/o NRI Growth Rate -28.90
3-Year EPS w/o NRI Growth Rate ranked higher than
88.69% of 663 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
CTLT: -28.9
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» CTLT's 30-Y Financials

Financials (Next Earnings Date: 2019-08-28)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:CTLT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare NSE:DIVISLAB SHSE:600085 OSTO:SOBI BOM:500124 NSE:AUROPHARMA NYSE:PRGO TSE:4508 SZSE:300142 SZSE:002001 SZSE:000963 TSE:4581 BOM:500257 TSX:CRON SZSE:002773 LSE:HIK SHSE:600518 NAS:TLRY SHSE:600535 TSX:BHC SZSE:300601
Traded in other countries 0C8.Germany
Address 14 Schoolhouse Road, Somerset, NJ, USA, 08873
Catalent is a specialty and generic drug manufacturing company. The company focuses on advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. The vast majority of Catalent's sales are generated in the United States, followed by Europe and the rest of the world. Most of the company's sales are derived from branded drug products. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Ratios

Current vs industry vs history
PE Ratio (TTM) 43.60
PE Ratio ranked lower than
90.48% of 557 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
CTLT: 43.6
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 12.04, Med: 38.83, Max: 159.94
Current: 43.6
12.04
159.94
Forward PE Ratio 22.88
Forward P/E ranked higher than
52.25% of 111 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
CTLT: 22.88
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 43.60
PE without NRI ranked lower than
90.11% of 556 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
CTLT: 43.6
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 12.04, Med: 38.91, Max: 169.35
Current: 43.6
12.04
169.35
Price-to-Owner-Earnings 54.30
Price-to-Owner-Earnings ranked lower than
51.85% of 324 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
CTLT: 54.3
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 23.43, Med: 30.7, Max: 60.06
Current: 54.3
23.43
60.06
PB Ratio 4.19
PB Ratio ranked lower than
74.85% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
CTLT: 4.19
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.84, Med: 5.4, Max: 8.48
Current: 4.19
2.84
8.48
PS Ratio 2.65
PS Ratio ranked higher than
61.16% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
CTLT: 2.65
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.4, Med: 1.97, Max: 2.65
Current: 2.65
1.4
2.65
Price-to-Free-Cash-Flow 86.05
Price-to-Free-Cash-Flow ranked higher than
56.38% of 298 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
CTLT: 86.05
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 23.66, Med: 34.82, Max: 256.24
Current: 86.05
23.66
256.24
Price-to-Operating-Cash-Flow 24.80
Price-to-Operating-Cash-Flow ranked higher than
71.94% of 392 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
CTLT: 24.8
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 11.27, Med: 17.17, Max: 30.99
Current: 24.8
11.27
30.99
EV-to-EBIT 31.06
EV-to-EBIT ranked lower than
73.43% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
CTLT: 31.06
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 18, Med: 25.2, Max: 37.7
Current: 31.06
18
37.7
EV-to-EBITDA 17.16
EV-to-EBITDA ranked lower than
56.95% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
CTLT: 17.16
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 11.5, Med: 15.3, Max: 22.2
Current: 17.16
11.5
22.2
EV-to-Revenue 3.50
EV-to-Revenue ranked lower than
51.82% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
CTLT: 3.5
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 2.2, Med: 3, Max: 3.8
Current: 3.5
2.2
3.8
PEG Ratio 21.40
PEG Ratio ranked lower than
100.00% of 317 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1472, Med: 1.93, Min: 0.07
CTLT: 21.4
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 9.66, Med: 28.47, Max: 70.96
Current: 21.4
9.66
70.96
Current Ratio 2.18
Current Ratio ranked lower than
54.39% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
CTLT: 2.18
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.51, Med: 1.96, Max: 2.91
Current: 2.18
1.51
2.91
Quick Ratio 1.71
Quick Ratio ranked lower than
52.05% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
CTLT: 1.71
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.14, Med: 1.53, Max: 2.49
Current: 1.71
1.14
2.49
Days Inventory 49.54
Days Inventory ranked higher than
86.23% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
CTLT: 49.54
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 19.07, Med: 40.19, Max: 49.54
Current: 49.54
19.07
49.54
Days Sales Outstanding 85.96
Days Sales Outstanding ranked higher than
52.86% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
CTLT: 85.96
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 72.58, Med: 80.62, Max: 85.97
Current: 85.96
72.58
85.97
Days Payable 43.55
Days Payable ranked lower than
79.42% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
CTLT: 43.55
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 38.5, Med: 41.93, Max: 44.69
Current: 43.55
38.5
44.69

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -2.40
3-Year Share Buyback Rate ranked lower than
74.26% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
CTLT: -2.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -2.4, Med: -2.1, Max: 0
Current: -2.4
-2.4
0

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 3.23
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
72.73% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
CTLT: 3.23
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 2.23, Med: 3.35, Max: 3.92
Current: 3.23
2.23
3.92
Price-to-Median-PS-Value 1.35
Price-to-Median-PS-Value ranked lower than
66.22% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
CTLT: 1.35
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.8, Med: 0.94, Max: 1.35
Current: 1.35
0.8
1.35
Earnings Yield (Joel Greenblatt) % 3.23
Earnings Yield (Greenblatt) ranked higher than
51.56% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
CTLT: 3.23
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 2.6, Med: 4, Max: 5.5
Current: 3.23
2.6
5.5
Forward Rate of Return (Yacktman) % 3.96
Forward Rate of Return ranked lower than
70.07% of 421 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
CTLT: 3.96
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 2.6, Med: 3.9, Max: 8.5
Current: 3.96
2.6
8.5

More Statistics

Revenue (TTM) (Mil) $ 2,477.6
EPS (TTM) $ 1.06
Beta 2.02
Volatility % 40.31
52-Week Range $ 29.23 - 47.04
Shares Outstanding (Mil) 145.72

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N